GM Canada Workers Approve C$1.1 Billion Investment Deal 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Toyota Global Sales Fall as China Demand Slumps 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
CIA-Linked Investor Helped Quantum Systems Expand in US 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Add as a preferred source on Google
SAN DIEGO, April 03, 2018 -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced the company has raised $30.5 million in an oversubscribed Series B financing round, led by Longitude Capital. Additional new investors included Vivo Capital and the Tavistock Group, joined by existing investor Malin Corporation plc. In conjunction with the financing, David Hirsch, M.D., Ph.D., managing director at Longitude Capital, has joined Poseida’s Board of Directors.
Proceeds from this financing will be used to further advance a pipeline of autologous and allogeneic CAR-T immunotherapies, as well as gene therapies, using Poseida’s suite of gene engineering technologies. P-BCMA-101 is a CAR-T therapy currently in Phase 1 clinical development for relapsed/refractory multiple myeloma, with initial clinical data accepted for presentation at the upcoming AACR Annual Meeting. P-PSMA-101 is a CAR-T therapy in preclinical development for the treatment of prostate cancer. P-BCMA-ALLO1 is an allogeneic “universal donor” CAR-T for multiple myeloma.
“We have shown across multiple programs, in preclinical and in clinical studies, an ability to use our proprietary gene engineering technologies to develop advanced CAR-T therapies with more favorable cell phenotype profiles and other highly desirable features that overcome limitations of first generation CAR-T therapies,” said Eric Ostertag, M.D., Ph.D., chief executive officer at Poseida. “With this latest infusion of capital, Poseida will continue on its path to rapidly complete a Phase 1 study of P-BCMA-101 in multiple myeloma and file an Investigational New Drug application for our second and third CAR-T programs, P-PSMA-101 for prostate cancer and P-BCMA-ALLO1 for multiple myeloma, while also moving additional promising pipeline candidates forward enabled by our best-in-class gene engineering technologies.”
About Poseida Therapeutics, Inc.
Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida’s lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac™ DNA Modification System, TAL-CLOVER™ and Cas-CLOVER™ site-specific nucleases, and Footprint-Free™ Gene Editing (FFGE). For more information, visit www.poseida.com.
Poseida has received grant funding from the California Institute for Regenerative Medicine to support the clinical development of P-BCMA-101.
Corporate Communications Contact:
Jason Spark
Canale Communications
619-849-6005
[email protected]
